Associated tags: Proteome, Research, Automation, Software, Proteomics, Seer
Locations: NEW YORK, CALIFORNIA, GERMANY, BOSTON, MA, NY, TD, REDWOOD CITY, CA, US, EUROPE
STAC,
Seer,
CCO,
Health,
University Hospital Bonn,
Proteomics,
Research,
Workflow,
Proteome,
Disease,
Life,
Automation,
Biology,
Mass spectrometry,
Drug development REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, announced the launch of the Seer Technology Access Center (STAC) in Bonn, Germany, providing the European biopharma and life sciences communities with service programs and the latest mass spectrometry technologies to optimize deep, unbiased proteomic studies. The new facility, opening in June, will be located at Life & Brain GmbH, an independent commercial technology provider, on the campus of the University Hospital Bonn. In June 2023, Seer established the first Seer Technology Access Center at the company’s headquarters in Redwood City, California.
Key Points:
- The new facility, opening in June, will be located at Life & Brain GmbH, an independent commercial technology provider, on the campus of the University Hospital Bonn.
- In June 2023, Seer established the first Seer Technology Access Center at the company’s headquarters in Redwood City, California.
- The Seer Technology Access Center in Europe will help address an unmet need for researchers who want to conduct deep, unbiased proteomics studies to accelerate biomarker discovery and drug development.
- To learn more about Seer’s Technology Access Center, contact your local Seer representative by requesting a consultation at www.seer.bio .
REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the first quarter ended March 31, 2024.
Key Points:
- REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the first quarter ended March 31, 2024.
- Gross profit, inclusive of grant and other revenue, was $1.4 million and gross margin was 44% for the first quarter of 2024.
- Net loss was $20.7 million for the first quarter of 2024, as compared to $24.0 million for the corresponding prior year period.
- Seer will host a conference call to discuss the first quarter 2024 financial results on Wednesday, May 8, 2024 at 1:30 pm Pacific Time / 4:30 pm Eastern Time.
REDWOOD CITY, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the first quarter 2024 on Wednesday, May 8, 2024.
Key Points:
- REDWOOD CITY, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the first quarter 2024 on Wednesday, May 8, 2024.
- Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
- Live audio of the webcast will be available on the Investor section of Seer’s website at investor.seer.bio.
- An archived replay will be available on the company’s website following the event.
Retrieved on:
Thursday, February 29, 2024
REDWOOD CITY, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the fourth quarter and full year ended December 31, 2023.
Key Points:
- REDWOOD CITY, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the fourth quarter and full year ended December 31, 2023.
- Gross profit, inclusive of grant and other revenue, was $2.0 million and gross margin was 45.1% for the fourth quarter of 2023.
- Net loss was $17.8 million for the fourth quarter of 2023, as compared to $22.5 million for the corresponding prior year period.
- Seer will host a conference call to discuss the fourth quarter and full year 2023 financial results on Thursday, February 29, 2024 at 1:30 pm Pacific Time / 4:30 pm Eastern Time.
Retrieved on:
Wednesday, February 21, 2024
REDWOOD CITY, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming TD Cowen 44th Annual Health Care Conference in Boston, MA.
Key Points:
- REDWOOD CITY, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming TD Cowen 44th Annual Health Care Conference in Boston, MA.
- Seer’s management is scheduled to participate in a fireside chat and Q&A session on Monday, March 4th at 1:30 p.m. Eastern Time / 10:30 a.m. Pacific Time.
- A live webcast of the session will be available on the Investor section of Seer’s website at investor.seer.bio.
- An archived replay will be available on the company’s website following the conference.
Retrieved on:
Tuesday, February 6, 2024
Marker beacon,
Manuscript,
Bioinformatics,
Peptide,
Weill Cornell Medicine,
Research,
Genetic variation,
Nature Communications,
Cardiovascular disease,
Gene,
Nanoparticle,
Proteome,
Metabolomics,
GIP,
Drug discovery,
Mass spectrometry,
Protein,
Medicine,
Biophysics,
Proteomics,
Physiology,
Plasma REDWOOD CITY, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced a publication in Nature Communications from a study led by Weill Cornell Medicine showing Seer’s Proteograph workflow to potentially unveil novel proteogenomic insights into genetics-based drug and biomarker discovery for precision medicines. Designed to address the challenges with affinity-based proteomic approaches for protein quantitative trait loci (pQTL) studies, the scalable, high-resolution Proteograph workflow enables scientists to link genetic variation with protein abundance with peptide level resolution.
Key Points:
- The study found 184 PAVs in 137 genes, confirmed by their variant peptides in mass spectrometry data, known as MS-PAV.
- Most MS-PAVs were aligned with known genetic markers (cis-pQTLs), validating the target specificity of the method.
- Seer's approach provides customers with unparalleled insights into drug response analysis, drug discovery, patient stratifications for clinical studies, and precision medicine.
- “At Seer, we offer researchers a new method for pQTL mapping and a deeper understanding of proteins and peptides for large-scale proteogenomic studies.”
Retrieved on:
Thursday, February 1, 2024
REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the fourth quarter and full year 2023 on Thursday, February 29, 2024.
Key Points:
- REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the fourth quarter and full year 2023 on Thursday, February 29, 2024.
- Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
- Live audio of the webcast will be available on the Investor section of Seer’s website at investor.seer.bio.
- An archived replay will be available on the company’s website following the event.
Retrieved on:
Thursday, December 21, 2023
REDWOOD CITY, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming J.P. Morgan 42nd Annual Health Care Conference in San Francisco, CA.
Key Points:
- REDWOOD CITY, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming J.P. Morgan 42nd Annual Health Care Conference in San Francisco, CA.
- Seer’s management is scheduled to present and participate in a Q&A session on Wednesday, January 10th at 3:00 p.m. Pacific Time / 6:00 p.m. Eastern Time.
- A live webcast of the session will be available on the Investor section of Seer’s website at investor.seer.bio.
- An archived replay will be available on the company’s website following the conference.
Retrieved on:
Friday, November 10, 2023
REDWOOD CITY, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced company management will be participating in the upcoming Canaccord MedTech, Diagnostics and Digital Health and Services Forum in New York, NY.
Key Points:
- REDWOOD CITY, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced company management will be participating in the upcoming Canaccord MedTech, Diagnostics and Digital Health and Services Forum in New York, NY.
- Seer’s management is scheduled to present on Thursday, November 16th at 1:00 p.m. Eastern Time / 10:00 a.m. Pacific Time.
- A live webcast of the session will be available on the Investor section of Seer’s website at investor.seer.bio.
- An archived replay will be available on the company’s website following the conference.
Retrieved on:
Wednesday, November 8, 2023
Fintech,
Health,
Therapy,
Deloitte Technology Fast 500,
Genomics,
SEER,
Telecommunications,
Seer,
Proteome,
Proteomics,
Biotechnology,
Pharmaceutical industry (NASDAQ: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company was selected as “Proteomics Solution of the Year” in the 2023 BioTech Breakthrough Awards program as well as being named to the 2023 Deloitte Technology Fast 500 .
Key Points:
- (NASDAQ: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company was selected as “Proteomics Solution of the Year” in the 2023 BioTech Breakthrough Awards program as well as being named to the 2023 Deloitte Technology Fast 500 .
- “We're thrilled to receive accolades from both BioTech Breakthrough and Deloitte, as these awards underscore our unwavering dedication to innovation, collaboration, and our mission to advance our understanding of human health.
- Seer also announced today that it ranked 5 on the Deloitte Technology Fast 500, a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 29th year.
- Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2019 to 2022.
